Made Differently to Make a Difference

High Purity n.c.a. Lu-177

Not all Lu-177 is created the same. Carrier-added forms contain impurities that dilute effectiveness and create more waste. SHINE's Ilumira is non-carrier-added Lu-177 with ≥ 99.9% purity, precisely targeting tumors and minimizing unnecessary radiation. That level of purity gives you greater confidence in every vial.

learn more

Continuous supply available

U.S.- based production and logistics

Currently being used in several active clinical trials underway globally

Inquire About Our Products

Thank you - Your submission has been received!

Oops! Something went wrong while submitting the form.

Purity in Practice

What ≥99.9% Purity Means for Care

n.c.a. Lu-177 purity at this level translates into clear, practical advantages.

Here’s what it means for patients and providers:

Effective irradiation: The higher specific activity of n.c.a. Lu-177 compared to c.a. Lu-177 ensures greater availability of radioactivity thus reducing the mass of non-radioactive carrier material administered. ²
‍
Reliable preparation. Consistent labeling yields (≈83–97% vs. 4–87% for c.a.) support predictable results across patients and programs.
‍
‍Lower waste burden. n.c.a. Lu-177 has a short half life and negligible long-lived impurities, simplifying hospital storage and disposal.

Precision in Practice

How Ilumira Targets Cancer

We supply Ilumira n.c.a. Lu-177 as a chloride solution in treated glass vials. Paired with a targeting molecule, it becomes a radiopharmaceutical that delivers therapeutic radiation where it’s needed most, while minimizing harm to healthy tissue. For patients who have exhausted other options, Ilumira offers new hope for cancer care³.

Two Paths, One Clear Choice

Carrier-Added vs. Non-Carrier-Added Lu-177²

Carrier-Added (c.a.)

Non-Carrier-Added (n.c.a.)

Composition

Lu-177 plus non-therapeutic isotopes (Lu-176, Lu-177m)

≥99.9% Lu-177

Specific Activity

Lower, variable (≈370-1110 GBq/mg)

Higher, consistent (up to ≈3700 GBq/mg)

Drug Preparation

Inconsistent labeling yields (≈5-90%)

Consistent labeling yields (≈90-99%)

Clinical Impact

Less efficient tumor binding→more residual isotope, higher side-effect risk

More efficient tumor binding→less residual isotope, lower side-effect risk

Waste Contamination

Long-lived impurities (e.g., Lu-177m, t½ ≈160 days) require extended storage and handling

Waste decays quickly (t½ ≈6.65 days), negligible long-lived contamination

Download Ilumira brochure

Quality Secured, Supply Assured

Production to Delivery: The Ilumira Advantage

Quality & Compliance

Ilumira achieves ≥99.9% purity, meeting both U.S. and European Pharmacopeia standards. Every batch is tested to confirm radiolabeling yield and performance, ensuring predictable results. Produced under cGMP standards and supported by an FDA Drug Master File, Ilumira delivers consistency you can trust.

Supply & Reliability

With weekly shipping, customers can place an order one week and receive it the next, keeping research and treatments on schedule. SHINE’s U.S.-based facility is scaled to support hundreds of thousands of doses each year⁴. Streamlined logistics and experience in international shipping further reduce delays and disruptions.

Independence & Security

We’re involved in every step of the process, from securing enriched Yb-176 through final shipment, ensuring a secure and reliable supply. SHINE is one of the few Lutetium producers that also recycles Ytterbium (Yb-176) thus reducing waste, improving efficiency, and de-risking supply. Made in the U.S. and ready for the world, Ilumira strengthens providers' resilience everywhere.

More Than a Supplier

Reliable Support and Expertise

SHINE offers dependable service that goes beyond supply. We test every lot to confirm quality and performance, coordinate timely delivery, and provide radiolabeling insight as needed. Weekly shipping keeps programs moving, and our expertise is always within reach.

Ilumira Product Specifications⁵

Packaging Options

10 mL flat bottom vial
2mL conical glass vial

Chemical form

n.c.a. ¹⁷⁷LuCl₃ in 0.04M HCI solution

specific activity

≥3,000 GBq/mg at SHINE calibration time

Radiochemical Purity

≥99% as ¹⁷⁷LuCl₃

Radionuclidic Purity

≥99.9% ¹⁷⁷Lu

Radioactivity Concentration at SHINE Calibration Time

1.0Ci/mL (37GBq/mL)

Expiry

10 days from the end of synthesis

Standard Calibration Time

Tuesdays 1200 central time (U.S) at 1.00 Ci/mL

cGMP

Meets ICH-Q7 and FDA-21CFR

Meets ICH Q7 and applicable provisions of FDA 21 CFR Parts 210 and 211

A Bright Path
for Cancer Care

Ilumira n.c.a. Lu-177 is produced with ≥99.9% purity at SHINE’s cGMP U.S. facility. That gives CDMOs, researchers, and providers consistency they can count on. Higher purity supports better radiolabeling, targeted elimination of cancer cells, reduced exposure to unnecessary radiation, and patient care that stays on schedule.

Ready to advance your targeted cancer therapies? Contact us today to learn how Ilumira can support your research or clinical program.

Download Ilumira Brochure

References

1. Niu T, Fan M, Lin B, et al. Current clinical application of lutetium-177 in solid tumors (Review). Exp Ther Med. 2024;27(5):225. doi:10.3892/etm.2024.12514. PMID: 38596660; PMCID: PMC11002837. Accessed April 30, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837
2. Dash A, Pillai MR, Knapp FF Jr. Production of 177Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49(2):85-107. doi:10.1007/s13139-014-0315-z. PMCID: PMC4463871. Accessed April 30, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4463871/

3. Nanabala R, Pillai MRA, Gopal B. Preparation of patient doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with carrier added (CA) and no carrier added (NCA) 177Lu. Nucl Med Mol Imaging. 2022;56(6):313-322. doi:10.1007/s13139-022-00778-y. Accessed April 30, 2026.
4. World Nuclear Association. Radioisotopes in medicine. World Nuclear Association Information Library. Accessed April 30, 2026. https://world-nuclear.org/information-library/non-power-nuclear-applications/radioisotopes-research/radioisotopes-in-medicine
5. Data on file at SHINE

‍

Note: Ilumira is a radiopharmaceutical precursor, not a finished drug. It is solely intended for radiolabeling of carrier molecules and is not for direct patient use.
©2026 SHINE Technologies, LLC | All Rights Reserved. | MKT.ILU.0022.V4

Ilumira: the Lu-177 Patients Deserve